Show simple item record

dc.contributor.authorDunican, E
dc.contributor.authorUzbeck, M
dc.contributor.authorClince, J
dc.contributor.authorToner, S
dc.contributor.authorRoyston, D
dc.contributor.authorLogan, M P
dc.contributor.authorBreathnach, O
dc.contributor.authorYoung, V
dc.contributor.authorLinnane, S I
dc.contributor.authorMorgan, R K
dc.date.accessioned2012-02-01T10:03:26Z
dc.date.available2012-02-01T10:03:26Z
dc.date.issued2012-02-01T10:03:26Z
dc.identifier.citationIr Med J. 2011 Oct;104(9):265-8.en_GB
dc.identifier.issn0332-3102 (Print)en_GB
dc.identifier.issn0332-3102 (Linking)en_GB
dc.identifier.pmid22132593en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207263
dc.description.abstractWe examined the outcomes of the first 500 patients referred to a dedicated Rapid Access Lung Cancer Clinic. A total of 206 patients (41.2%) were diagnosed with a thoracic malignancy; 179 had primary lung cancer and 27 had secondary or other thoracic cancers. Pulmonary nodules requiring ongoing surveillance were found in a further 79 patients (15.8%). Of those patients found to have primary lung cancer, 24 (13.4%) had Small Cell and 145 (81%) had Non Small Cell Lung Cancer. In patients with Non small cell tumours, 26 (21.1%) were stage 1, 14 (11.4%) stage II, 37 (30.1%) stage III and 46 (37.4%) stage IV at diagnosis. For the 129 patients (72%) in whom the thoracic MDT recommended active treatment, primary therapy was surgical resection in 44 (24.6%), combined chemoradiation in 31 patients (17.3%), chemotherapy alone in 39 (21.8%) and radiation in 15 (8.4%).
dc.language.isoengen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshCarcinoma, Non-Small-Cell Lung/diagnosis/epidemiology/therapyen_GB
dc.subject.meshCombined Modality Therapyen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIreland/epidemiologyen_GB
dc.subject.meshLung Neoplasms/*diagnosis/epidemiology/*therapyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMesothelioma/diagnosis/epidemiology/therapyen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshNeoplasm Stagingen_GB
dc.subject.mesh*Outpatient Clinics, Hospitalen_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshSmall Cell Lung Carcinoma/diagnosis/epidemiology/therapyen_GB
dc.subject.meshYoung Adulten_GB
dc.titleOutcomes of patients presenting to a dedicated rapid access lung cancer clinic.en_GB
dc.contributor.departmentDepartment of Respiratory Medicine and Thoracic Oncology, Beaumont Hospital,, Beaumont, Dublin 9.en_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinster
refterms.dateFOA2018-08-22T15:42:05Z
html.description.abstractWe examined the outcomes of the first 500 patients referred to a dedicated Rapid Access Lung Cancer Clinic. A total of 206 patients (41.2%) were diagnosed with a thoracic malignancy; 179 had primary lung cancer and 27 had secondary or other thoracic cancers. Pulmonary nodules requiring ongoing surveillance were found in a further 79 patients (15.8%). Of those patients found to have primary lung cancer, 24 (13.4%) had Small Cell and 145 (81%) had Non Small Cell Lung Cancer. In patients with Non small cell tumours, 26 (21.1%) were stage 1, 14 (11.4%) stage II, 37 (30.1%) stage III and 46 (37.4%) stage IV at diagnosis. For the 129 patients (72%) in whom the thoracic MDT recommended active treatment, primary therapy was surgical resection in 44 (24.6%), combined chemoradiation in 31 patients (17.3%), chemotherapy alone in 39 (21.8%) and radiation in 15 (8.4%).


Files in this item

Thumbnail
Name:
Article6383.pdf
Size:
11.03Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record